Ascentage Pharma
AAPG
7 hedge funds and large institutions have $722K invested in Ascentage Pharma in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 5 closing their positions.
0.02% less ownership
Funds ownership: 0.05% → 0.03% (-0.02%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
42% less funds holding
Funds holding: 12 → 7 (-5)
42% less capital invested
Capital invested by funds: $1.25M → $722K (-$531K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$8.49K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$255K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$101K |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$66.8K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.5K |
| 5 |
XC
XY Capital
Central,
Hong Kong
|
-$15.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Point72 Asset Management
Stamford,
Connecticut
| $383K | -$16.5K | -670 | -4% |
|
|
XC
2
XY Capital
Central,
Hong Kong
| $311K | -$15.1K | -614 | -5% |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $12.4K | +$7.09K | +288 | +125% |
|
|
4
Morgan Stanley
New York
| $11.9K | +$8.49K | +345 | +225% |
|
|
5
UBS Group
Zurich,
Switzerland
| $2.96K | -$101K | -4,108 | -97% |
|
|
EWA
6
EverSource Wealth Advisors
Birmingham,
Alabama
| $573 | – | – | – |
|
|
7
Citadel Advisors
Miami,
Florida
| – | -$255K | -9,737 | Closed |
|
|
8
Mirae Asset Global Investments
Seoul,
South Korea
| – | -$66.8K | -2,546 | Closed |
|
9
Osaic Holdings
Scottsdale,
Arizona
| – | -$5.77K | -220 | Closed |
|
10
Bank of America
Charlotte,
North Carolina
| – | -$5.27K | -201 | Closed |
|
|
BIA
11
Bell Investment Advisors
Oakland,
California
| – | -$1.76K | -67 | Closed |
|
AAPG Hedge Fund Activity: Q1 2026 in Review
7 of the 8,150 institutional investors tracked by Wall St. Rank reported a position in Ascentage Pharma (AAPG) for Q1 2026, worth a combined $722K — down 42% from $1.25M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of AAPG and 0 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Morgan Stanley, adding an estimated $8.49K. The largest seller was Citadel Advisors, exiting entirely with an estimated $255K sold.
- 7 institutional investors held Ascentage Pharma (AAPG) as of Q1 2026, down from 12 in Q4 2025.
- Funds reported $722K of Ascentage Pharma stock for Q1 2026, down 42% quarter-over-quarter.
- 0 funds opened new Ascentage Pharma positions in Q1 2026 and 5 closed out, a net change of -5 holders.
- The largest Ascentage Pharma buyer in Q1 2026 was Morgan Stanley, an estimated $8.49K added.
- The largest Ascentage Pharma seller in Q1 2026 was Citadel Advisors, an estimated $255K sold.
Based on aggregated 13F filings for Q1 2026.